"V体育官网" NRF2 modulation in TRAMP mice: an in vivo model of prostate cancer
- PMID: 36335520
- DOI: 10.1007/s11033-022-08052-2
NRF2 modulation in TRAMP mice: an in vivo model of prostate cancer
Abstract
Background: Prostate cancer (PCa) is one of the most common cancers worldwide and oxidative stress is involved in its occurrence, development and progression. In fact, in transgenic adenocarcinoma of mouse prostate (TRAMP) mice, prostate cancer onset is associated with the methylation of the first five CpG in the nuclear factor erythroid 2-related factor 2 (NRF2) promoter, a key regulator of oxidative stress response, leading to its downregulation and accumulation of reactive oxygen species (ROS). It has been demonstrated that both natural and synthetic compounds can reactivate NRF2 expression inhibiting the methylation status of its promoter by downregulation of DNA methyltransferases (DNMTs) and histone deacetylases (HDACs). Interestingly, NRF2 re-expression significantly reduced prostate cancer onset in TRAMP mice highlighting an important role of NRF2 in prostate tumorigenesis. VSports手机版.
Methods and results: We analysed the current literature regarding the role of natural and synthetic compounds in modulating NRF2 pathway in TRAMP mice, an in vivo model of prostate cancer, to give an overview on prostate carcinogenesis and its possible prevention V体育安卓版. .
Conclusion: We can conclude that specific natural and synthetic compounds can downregulate DNMTs and/or HDACs inhibiting the methylation status of NRF2 promoter, then reactivating the expression of NRF2 protecting normal prostatic cells from ROS damage and tumorigenesis V体育ios版. .
Keywords: Carcinogenesis; Compounds; NRF2; Prostate cancer; Signaling; TRAMP mice VSports最新版本. .
© 2022. The Author(s), under exclusive licence to Springer Nature B V体育平台登录. V. .
References
-
- The Lancet O (2018) New interventions offer prostate cancer hope. Lancet Oncol 19(4):427. https://doi.org/10.1016/S1470-2045(18)30219-5 - DOI
-
- Perlmutter MA, Lepor H (2007) Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 9(Suppl 1):S3-8
-
- Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68(11):4447–4454. "V体育ios版" https://doi.org/10.1158/0008-5472.CAN-08-0249 - DOI
-
- Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO et al (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92(8):3439–3443. "V体育官网" https://doi.org/10.1073/pnas.92.8.3439 - DOI
-
- Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57(16):3325–3330
Publication types
MeSH terms
- V体育平台登录 - Actions
- Actions (VSports)
- V体育ios版 - Actions
- "VSports在线直播" Actions
- "VSports注册入口" Actions
- Actions (V体育平台登录)
- "VSports手机版" Actions
- "VSports手机版" Actions
Substances
- Actions (V体育官网入口)
Grants and funding
LinkOut - more resources
Full Text Sources
Medical